MedTrace Logo

Lapatinib in Combination With Vinorelbine

NCT01013740 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2017-05-31

Study results available
· View outcomes & findings →

Summary

This is a randomized, parallel-arm, open-label, multi-centre, Phase II study to determine the efficacy and safety of lapatinib in combination with vinorelbine or capecitabine in women with ErbB2 overexpressing metastatic breast cancer (MBC) who have received no more than one chemotherapeutic regimen in the metastatic setting.

Conditions

Interventions

DRUG

Vinorelbine

Vinorelbine

DRUG

Lapatinib

Lapatinib

DRUG

Capecitabine

Capecitabine

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-25
Primary Completion
2012-08-21
Completion
2016-03-01

Countries

  • Bulgaria
  • Chile
  • France
  • Germany
  • Greece
  • Italy
  • Mexico
  • Poland
  • Serbia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01013740 on ClinicalTrials.gov